Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma arising from the gallbladder. It is the most common malignant tumor of the gallbladder and it is usually well to moderately differentiated. The incidence is higher in patients with gallstones than in patients without gallstones. Signs and symptoms usually present late in the course of the disease and are reminiscent of those of chronic cholecystitis including right upper quadrant pain. Histologic variants include adenocarcinoma of the intestinal type, clear cell adenocarcinoma, mucinous adenocarcinoma, papillary adenocarcinoma, and signet ring adenocarcinoma. 
Gallbladder adenocarcinomas most frequently harbor alterations in TP53, CDKN2A, SMAD4, ERBB2, and ARID1A .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, TP53 Exon 7 Mutation, and TP53 Exon 8 Mutation are the most common alterations in gallbladder adenocarcinoma .
There are 5 clinical trials for gallbladder adenocarcinoma, of which 3 are open and 2 are completed or closed. Of the trials that contain gallbladder adenocarcinoma as an inclusion criterion, 3 are phase 1 (1 open) and 2 are phase 2 (2 open).
Cisplatin, gemcitabine, and pegph20 are the most common interventions in gallbladder adenocarcinoma clinical trials.
Significant Genes in Gallbladder Adenocarcinoma
UGT1A1 is an inclusion eligibility criterion in 1 clinical trial for gallbladder adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains UGT1A1 status and gallbladder adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.